Search details
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Article
in English
| MEDLINE | ID: mdl-37163621
2.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Article
in English
| MEDLINE | ID: mdl-37172204
3.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38821083
4.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37944541
5.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Blood
; 137(5): 637-645, 2021 02 04.
Article
in English
| MEDLINE | ID: mdl-32870269
6.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(6): 818-828, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35654052
7.
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Br J Haematol
; 193(6): 1123-1133, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33973233
8.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Article
in English
| MEDLINE | ID: mdl-32305093
9.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol
; 190(5): 736-740, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32236950
10.
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Haematologica
; 105(10): 2440-2447, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-33054084
11.
Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Am J Hematol
; 95(6): 643-651, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32129511
12.
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 104(10): 2053-2060, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31097627
13.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Article
in English
| MEDLINE | ID: mdl-26639149
14.
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Blood
; 137(8): 1117-1120, 2021 02 25.
Article
in English
| MEDLINE | ID: mdl-33027809
15.
Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI.
J Magn Reson Imaging
; 48(4): 897-906, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29656584
16.
Ibrutinib Regimens in Older Patients with Untreated CLL.
N Engl J Med
; 380(17): 1679-1681, 2019 04 25.
Article
in English
| MEDLINE | ID: mdl-31018080
17.
A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Eur J Haematol
; 98(2): 112-120, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27557853
18.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26655421
19.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Lancet
; 385(9980): 1873-83, 2015 May 09.
Article
in English
| MEDLINE | ID: mdl-25882396
20.
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
Ann Hematol
; 95(7): 1077-87, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27130310